CN106692480A - Western medicine for treating ventilation function failure - Google Patents

Western medicine for treating ventilation function failure Download PDF

Info

Publication number
CN106692480A
CN106692480A CN201611234749.8A CN201611234749A CN106692480A CN 106692480 A CN106692480 A CN 106692480A CN 201611234749 A CN201611234749 A CN 201611234749A CN 106692480 A CN106692480 A CN 106692480A
Authority
CN
China
Prior art keywords
parts
western medicine
ketone
treatment
ventilatory function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201611234749.8A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Eight Ling Electronic Technology Co Ltd
Original Assignee
Henan Eight Ling Electronic Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Eight Ling Electronic Technology Co Ltd filed Critical Henan Eight Ling Electronic Technology Co Ltd
Priority to CN201611234749.8A priority Critical patent/CN106692480A/en
Publication of CN106692480A publication Critical patent/CN106692480A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a Western medicine for treating ventilation function failure. The Western medicine for treating ventilation function failure mainly comprises the following raw materials in parts by weight: 9-13 parts of crocin, 25-30 parts of halofuginone, 7-10 parts of osmundacetone, 2-3 parts of 3-acetyl-11-ketoboswellic acid, 15-20 parts of tea polyphenol, 8-16 parts of d-tetrahydrojatrorrhizine, 5-14 parts of corynoline, 2-8 parts of paclitaxel, 9-12 parts of lupeol and 5-7 parts of isofraxidin. In the medicine disclosed by the invention, the ingredients are strictly chosen according to the known mechanism of ventilation function failure so as to achieve an aim of comprehensive rehabilitation; and the medicine has the characteristics of fast effect, stable action, convenience in carrying and taking and no toxic or side effect caused by long-term administration.

Description

A kind of Western medicine for treating ventilatory function exhaustion
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of Western medicine for treating ventilatory function exhaustion.
Background technology
Chronic exhaling is declined more secondary to chronic respiratory disease, such as chronic obstructive pulmonary disease, far advanced tuberculosis；Its breathing Functional lesion is gradually aggravated, though having anoxic and carbon dioxide retention, by the compensatory adaptation of body, is still engaged in personal lifestyle, is claimed It is compensatory ventilatory function exhaustion；Once generation respiratory tract infection, or because other reasonses increase physiology of respiration burden, then compensatory mistake Adjust, the clinical manifestation of severe depletion of oxygen, carbon dioxide retention and respiratory acidosis occur, referred to as decompensation ventilatory function declines Exhaust.Respiratory failure is anoxic or with carbon dioxide pool caused by the ventilation and (or) dysfunction of ventilation caused by various diseases Stay.Under sea level breathing atmospheric conditions, arterial partial pressure of oxygen (PaO2) is less than 8kPa and arterial partial pressure of carbon dioxide (PaCO2) it is higher than 6.66kPa, and produces the clinical syndrome of serial pathophysiological change and metabolic disorder.Lung governing qi, can exhale Inhale, clear gas, breathes out foul smell in suction air, is communicated with air, be the hinge of mechanism of qi discrepancy lifting.Lung being a delicate viscus, outer conjunction fur. Exopathogen is attacked human body attacking the lung first, impairment of dispersing and descending function of the lung and sends out cough and asthma.If obstinate disease can cause deficiency and damage of lung-QI, and involve spleen kidney.The deficiency syndrome of the lung The operation for administering painstaking effort can not be adjusted, then motive heart-yang also virtual loss, eventually to lung, spleen, kidney, all void of the heart and turn into the morbidity base of this disease Plinth.The factors such as climate change, diet, feelings will and fatigue, then can induce for this disease.Lack effective medicine at present.
The content of the invention
It is an object of the invention to provide a kind of Western medicine for treating ventilatory function exhaustion, to solve to be carried in above-mentioned background technology The problem for going out.
To achieve the above object, the present invention provides following technical scheme：
A kind of Western medicine for treating ventilatory function exhaustion, be according to the primary raw material of weight portion：Crocin 9-13 parts, Changshan Ketone 25-30 parts, 7-10 parts of osmund ketone, 2-3 parts of 3- acetyl group -11- ketone group masticinic acids, Tea Polyphenols 15-20 parts, D- tetrahydrojatrorrhizines 8-16 parts, corynoline 5-14 parts, taxol 2-8 parts, lupeol 9-12 parts, isofraxidin 5-7 parts.
As further scheme of the invention：The Western medicine of the treatment ventilatory function exhaustion, according to the main original of weight portion Expect be：Crocin 10-11 parts, halofuginone hydrobromide 26-28 parts, 8-9 parts of osmund ketone, 2-3 parts of 3- acetyl group -11- ketone group masticinic acids, tea Polyphenol 16-19 parts, 12-15 parts of D- tetrahydrojatrorrhizines, corynoline 7-12 parts, taxol 3-7 parts, lupeol 10-11 parts, different piperazine 5-7 parts of skin pyridine.
As further scheme of the invention：The Western medicine of the treatment ventilatory function exhaustion, according to the main original of weight portion Expect be：11 parts of crocin, 27 parts of halofuginone hydrobromide, 9 parts of osmund ketone, 3 parts of 3- acetyl group -11- ketone groups masticinic acid, 18 parts of Tea Polyphenols, 14 parts of D- tetrahydrojatrorrhizines, 9 parts of corynoline, 5 parts of taxol, 11 parts of lupeol, 6 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating ventilatory function exhaustion, concretely comprises the following steps：
First, in pharmaceutical grade clean area, crocin, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio Base -11- ketone groups masticinic acid, Tea Polyphenols, D- tetrahydrojatrorrhizines, corynoline, taxol, lupeol, isofraxidin, sieving, machine Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4-8min, controls RSD≤5%, compressing tablet and low temperature after mixing Dry, at 4-8 DEG C, packaging obtains final product the Western medicine for the treatment of ventilatory function exhaustion to temperature control.
As further scheme of the invention：Mix 6min in specific steps.
Compared with prior art, the beneficial effects of the invention are as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of ventilatory function exhaustion, complete so as to reach The purpose of face rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described, Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all Belong to the scope of protection of the invention.
Embodiment 1
A kind of Western medicine for treating ventilatory function exhaustion, be according to the primary raw material of weight portion：9 parts of crocin, halofuginone hydrobromide 25 parts, 7 parts of osmund ketone, 2 parts of 3- acetyl group -11- ketone groups masticinic acid, 15 parts of Tea Polyphenols, 8 parts of D- tetrahydrojatrorrhizines, corynoline 5 Part, 2 parts of taxol, 9 parts of lupeol, 5 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating ventilatory function exhaustion, concretely comprises the following steps：
First, in pharmaceutical grade clean area, crocin, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio Base -11- ketone groups masticinic acid, Tea Polyphenols, D- tetrahydrojatrorrhizines, corynoline, taxol, lupeol, isofraxidin, sieving, machine Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing Dry, at 4 DEG C, packaging obtains final product the Western medicine for the treatment of ventilatory function exhaustion to temperature control.
Embodiment 2
A kind of Western medicine for treating ventilatory function exhaustion, be according to the primary raw material of weight portion：10 parts of crocin, halofuginone hydrobromide 26 parts, 8 parts of osmund ketone, 2 parts of 3- acetyl group -11- ketone groups masticinic acid, 16 parts of Tea Polyphenols, 12 parts of D- tetrahydrojatrorrhizines, corynoline 7 Part, 3 parts of taxol, 10 parts of lupeol, 5 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating ventilatory function exhaustion, concretely comprises the following steps：
First, in pharmaceutical grade clean area, crocin, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio Base -11- ketone groups masticinic acid, Tea Polyphenols, D- tetrahydrojatrorrhizines, corynoline, taxol, lupeol, isofraxidin, sieving, machine Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing Dry, at 4 DEG C, packaging obtains final product the Western medicine for the treatment of ventilatory function exhaustion to temperature control.
Embodiment 3
A kind of Western medicine for treating ventilatory function exhaustion, be according to the primary raw material of weight portion：11 parts of crocin, halofuginone hydrobromide 27 parts, 9 parts of osmund ketone, 3 parts of 3- acetyl group -11- ketone groups masticinic acid, 18 parts of Tea Polyphenols, 14 parts of D- tetrahydrojatrorrhizines, corynoline 9 Part, 5 parts of taxol, 11 parts of lupeol, 6 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating ventilatory function exhaustion, concretely comprises the following steps：
First, in pharmaceutical grade clean area, crocin, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio Base -11- ketone groups masticinic acid, Tea Polyphenols, D- tetrahydrojatrorrhizines, corynoline, taxol, lupeol, isofraxidin, sieving, machine Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 6min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing Dry, at 6 DEG C, packaging obtains final product the Western medicine for the treatment of ventilatory function exhaustion to temperature control.
Embodiment 4
A kind of Western medicine for treating ventilatory function exhaustion, be according to the primary raw material of weight portion：11 parts of crocin, halofuginone hydrobromide 28 parts, 9 parts of osmund ketone, 3 parts of 3- acetyl group -11- ketone groups masticinic acid, 19 parts of Tea Polyphenols, 15 parts of D- tetrahydrojatrorrhizines, corynoline 12 Part, 7 parts of taxol, 11 parts of lupeol, 7 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating ventilatory function exhaustion, concretely comprises the following steps：
First, in pharmaceutical grade clean area, crocin, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio Base -11- ketone groups masticinic acid, Tea Polyphenols, D- tetrahydrojatrorrhizines, corynoline, taxol, lupeol, isofraxidin, sieving, machine Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing Dry, at 8 DEG C, packaging obtains final product the Western medicine for the treatment of ventilatory function exhaustion to temperature control.
Embodiment 5
A kind of Western medicine for treating ventilatory function exhaustion, be according to the primary raw material of weight portion：13 parts of crocin, halofuginone hydrobromide 30 parts, 10 parts of osmund ketone, 3 parts of 3- acetyl group -11- ketone groups masticinic acid, 20 parts of Tea Polyphenols, 16 parts of D- tetrahydrojatrorrhizines, corynoline 14 parts, 8 parts of taxol, 12 parts of lupeol, 7 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating ventilatory function exhaustion, concretely comprises the following steps：
First, in pharmaceutical grade clean area, crocin, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio Base -11- ketone groups masticinic acid, Tea Polyphenols, D- tetrahydrojatrorrhizines, corynoline, taxol, lupeol, isofraxidin, sieving, machine Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing Dry, at 8 DEG C, packaging obtains final product the Western medicine for the treatment of ventilatory function exhaustion to temperature control.
Pharmacology test
1st, chronic toxicity test
It is experiment with Western medicine obtained in the embodiment of the present invention 3, using gastric infusion mode, successive administration 2 times in 24h, Per minor tick 8h, 300mg/kg doses are administered every time, daily accumulation medicine total amount reaches 600mg medicines/kg, it is clinical equivalent to people to use 100 times of amount.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, and hair color light, its average weight is equal Increase with the extension of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney, brain, thymus gland, Stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).Result shows：Western medicine of the present invention without Chronic toxicity.
2nd, long term toxicity test
It is experiment with Western medicine obtained in the embodiment of the present invention 3, using gastric infusion mode, Western medicine of the present invention is divided into low dose Amount, middle dosage, three groups of high dose, the drug dose of each group is respectively 60,120,180mg medicines/kg/d, equivalent to clinical dosage 10,20,30 times.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematological indices, blood biochemical Mark without obvious influence, Systematic anatomy, organ coefficient and histopathological examination also no abnormal pathological change.Drug withdrawal 2 Also substantially change is had no week.Result shows：Western medicine of the present invention does not find overt toxicity reaction and postpones in long term toxicity test Toxic reaction.It can be seen that, Western medicine non-toxic reaction of the present invention, long-term prescription is safe and reliable.
3rd, clinical test
In September, 2015 is male 125 to outpatient service and in hospital ventilatory function failure patients 231 is collected between in March, 2016 altogether, Female 106,25~70 years old age, average age 45.8 years old, the course of disease 1~15 year.
Diagnostic criteria：
According to the diagnostic criteria of national ventilatory function exhaustion clinical speciality meeting：(1) there are the cause of disease of respiratory failure, such as air flue Occlusive disease, pulmonary parenchyma infiltration, pulmonary edema, Pulmonary Vascular disease, thorax and pleural diseases, anesthesia drug overdose, neuromuscular disease Or sleep apnea syndrome etc.；(2) there are anoxic or the clinical manifestation with carbon dioxide retention, such as expiratory dyspnea, purple Dark purple, Spirit nerve symptoms of disease etc..Occur the disturbance of consciousness, bulbar conjunctiva congestion and edema during concurrent pulmonary encephalopathy, papilledema, flutter The wing trembles.Severe patient can have hemorrhage of digestive tract；(3) blood gas analysis：In sea-level atmosphere pressure, under quiescent condition, in respiratory chamber Air arterial partial pressure of oxygen (PaO2) ＜ 8.0kPa (60mmHg), carbon dioxide partial pressure (PaCO：＞ 6.6kPa) (50mmHg) (or ≤ normal).
Treatment method：
, according to Western medicine obtained in specific embodiment 3,2 times a day for the oral present invention, and total amount is taken daily for 6mg/kg, 5 days It is 1 course for the treatment of, takes 2 courses for the treatment of.
Criterion of therapeutical effect：
It is effective：The clinical symptoms such as expiratory dyspnea, dry cough, crepitus (Velcro rales), cyanosis and sign are aobvious after treatment 15d Write and take a turn for the better, blood gas index is clearly better；Effectively：Expiratory dyspnea, dry cough, crepitus (Velcro rales), cyanosis etc. after treatment 15d Clinical symptoms and sign mitigate, and blood gas index takes a turn for the better；It is invalid：Clinical symptoms and sign, blood gas index do not change after treatment 15d Kind or deterioration.
Treatment results：
In 231 patients, effective 182, effective 29, invalid 20, total effective rate 91.3%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined May be appreciated other embodiment.

Claims (5)

1. a kind of Western medicine for treating ventilatory function exhaustion, it is characterised in that the primary raw material according to weight portion is：Crocin 9- 13 parts, halofuginone hydrobromide 25-30 parts, 7-10 parts of osmund ketone, 2-3 parts of 3- acetyl group -11- ketone group masticinic acids, Tea Polyphenols 15-20 parts, D- Tetrahydrojatrorrhizine 8-16 parts, corynoline 5-14 parts, taxol 2-8 parts, lupeol 9-12 parts, isofraxidin 5-7 parts.
2. it is according to claim 1 treatment ventilatory function exhaustion Western medicine, it is characterised in that the treatment ventilatory function declines The Western medicine for exhausting, be according to the primary raw material of weight portion：Crocin 10-11 parts, halofuginone hydrobromide 26-28 parts, 8-9 parts of osmund ketone, 3- 2-3 parts of acetyl group -11- ketone group masticinic acids, Tea Polyphenols 16-19 parts, 12-15 parts of D- tetrahydrojatrorrhizines, corynoline 7-12 parts, Japanese yew Alcohol 3-7 parts, lupeol 10-11 parts, isofraxidin 5-7 parts.
3. the Western medicine for the treatment of ventilatory function exhaustion according to claim 1 and 2, it is characterised in that the treatment is ventilated work( The Western medicine of energy exhaustion, be according to the primary raw material of weight portion：11 parts of crocin, 27 parts of halofuginone hydrobromide, 9 parts of osmund ketone, 3- acetyl 3 parts of base -11- ketone groups masticinic acid, 18 parts of Tea Polyphenols, 14 parts of D- tetrahydrojatrorrhizines, 9 parts of corynoline, 5 parts of taxol, lupeol 11 parts, 6 parts of isofraxidin.
4. it is a kind of as described in claim 1-3 is any treatment ventilatory function exhaustion Western medicine preparation method, it is characterised in that Concretely comprise the following steps：
First, in pharmaceutical grade clean area, crocin, halofuginone hydrobromide, osmund ketone, 3- acetyl group -11- are weighed by above-mentioned metering ratio Ketone group masticinic acid, Tea Polyphenols, D- tetrahydrojatrorrhizines, corynoline, taxol, lupeol, isofraxidin, sieving, machinery are mixed After add ultra-pure water, place in pharmacy mixer, mix 4-8min, control RSD≤5%, compressing tablet and low temperature drying after mixing, temperature At 4-8 DEG C, packaging obtains final product the Western medicine for the treatment of ventilatory function exhaustion for degree control.
5. it is according to claim 4 treatment ventilatory function exhaustion Western medicine preparation method, it is characterised in that specific steps Middle mixing 6min.
CN201611234749.8A 2016-12-28 2016-12-28 Western medicine for treating ventilation function failure Pending CN106692480A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611234749.8A CN106692480A (en) 2016-12-28 2016-12-28 Western medicine for treating ventilation function failure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611234749.8A CN106692480A (en) 2016-12-28 2016-12-28 Western medicine for treating ventilation function failure

Publications (1)

Publication Number Publication Date
CN106692480A true CN106692480A (en) 2017-05-24

Family

ID=58902879

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611234749.8A Pending CN106692480A (en) 2016-12-28 2016-12-28 Western medicine for treating ventilation function failure

Country Status (1)

Country Link
CN (1) CN106692480A (en)

Similar Documents

Publication Publication Date Title
Goudra et al. Anesthesia for advanced bronchoscopic procedures: state-of-the-art review
GB2431105A (en) Cannabinoids for the treatment of pulmonary disorders
US8394423B2 (en) Compositions comprising apocynin, ginkgo and ginger and uses thereof
CN104825778B (en) A kind of Chinese medicine composition for being used to treat calf pneumonia
CN106692480A (en) Western medicine for treating ventilation function failure
CN106619680A (en) Western medicine for treating chronic respiratory failure
CN106728286A (en) It is a kind of to treat Chinese and western medicinal composition of chronic respiratory failure and preparation method thereof
CN106727600A (en) It is a kind of to treat Chinese and western medicinal composition of bronchial astehma and preparation method thereof
Narita et al. Noninvasive ventilation improves the outcome of pulmonary complications after liver resection
CN102872324B (en) Traditional Chinese medicine atomized mixture for treating chest surgery postoperative respiratory distress syndrom
WO2015135372A1 (en) Application of isoforskolin in preventing and treating chronic obstructive pulmonary disease
CN105362226B (en) The preparation method of ambroxol albuterol aerosol
CN104189076B (en) A kind of Traditional Chinese medicine plaster for treating children's cold asthma and preparation method thereof
Sinha et al. ProSeal laryngeal mask airway in infants and toddlers with upper respiratory tract infections: a randomized control trial of spontaneous vs pressure control ventilation
CN108553554A (en) A kind of suppository and preparation method thereof for treating fever in children, palpitation with fear uneasiness, lung heat many coughs of phlegm
CN106822239A (en) It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof
CN106215080A (en) A kind of pharmaceutical composition for the treatment of bronchial asthma of child containing Procaterol Hydrochloride and preparation method thereof
EP4146189A1 (en) Glyceryltriacetate (gta) for use in improving breathing
Besnier et al. High-Flow Nasal Cannula Therapy: Principles and Potential Use in Obese Patients
CN111920785B (en) Inhalation preparation of iso-glycyrrhizic acid or salt thereof and application thereof
Zhou et al. What compromised the effect of reducing atelectasis by lung protective ventilation?
CN106619686A (en) Western medicine for treating bronchiectasis
CN105496993A (en) Preparing method of ambroxol salbutamol controlled release granule
Skouteris et al. Acute bronchial obstruction after nasotracheal intubation: Report of a case
Khan et al. SURGICAL MUSCLE RELAXATION: TO STUDY THE ADEQUACY IN PAEDIATRIC PATIENTS SCHEDULED FOR ELECTIVE GROIN SURGERIES UNDER GENERAL ANESTHESIA USING SEVOFLURANE WITHOUT NEUROMUSCULAR BLOCKING AGENTS.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170524

WD01 Invention patent application deemed withdrawn after publication